Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.

Cancer discovery - 1 Feb 2020

Cremer Anjali, Ellegast Jana M, Alexe Gabriela, Frank Elizabeth S, Ross Linda, Chu S Haihua, Pikman Yana, Robichaud Amanda, Goodale Amy, Häupl Björn, Mohr Sebastian, Rao Arati V, Walker Alison R, Blachly James S, Piccioni Federica, Armstrong Scott A, Byrd John C, Oellerich Thomas, Stegmaier Kimberly

Abstract excerpt

Spleen tyrosine kinase (SYK) is a nonmutated therapeutic target in acute myeloid leukemia (AML). Attempts to exploit SYK therapeutically in AML have shown promising results in combination with chemotherapy, likely reflecting induced mechanisms of resistance to single-agent treatment in vivo. We conducted a genome-scale open reading frame (ORF) resistance screen and identified activation of the RAS-MAPK-ERK...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Clinical Trials, Phase I as Topic
Share to Clinical Trials, Phase II as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Indazoles

Share to Mitogen-Activated Protein Kinase 1

Share to Primary Cell Culture

Share to Protein Tyrosine Phosphatase, Non-Receptor Type 11

Share to Pyrazines

Share to Syk Kinase

Source

Open in PubMed Open full text

Identifiers

PMID: 31771968
DOI: 10.1158/2159-8290.CD-19-0209
PMCID: PMC7058374

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 5 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Resistance Mechanisms to SYK Inhibition in Acute Myeloid Leukemia.PMID 31771968Read ↗

SYK is a critical regulator of FLT3 in acute myeloid leukemia.Semantic proximity Read ↗

Spleen tyrosine kinase as a molecular target for treatment of leukemias and lymphomasSemantic proximity Read ↗

Targeting AML Resistance with LY3009120-Sapanisertib and Ruxolitinib-Ulixertinib Combinations Demonstrate Superior Efficacy in <i>FLT3</i> , <i>TP53,</i> and <i>MUC4</i> mutationsSemantic proximity Read ↗

Expression of myeloid Src-family kinases is associated with poor prognosis in AML and influences Flt3-ITD kinase inhibitor acquired resistanceSemantic proximity Read ↗

Genome-wide CRISPR screen identifies regulators of MAPK and MTOR pathways mediating sorafenib resistance in acute myeloid leukemia.Semantic proximity Read ↗

Therapeutic potential of spleen tyrosine kinase inhibition for treating high-risk precursor B cell acute lymphoblastic leukemia.Semantic proximity Read ↗

SYK inhibition and response prediction in diffuse large B-cell lymphomaSemantic proximity Read ↗

Spleen tyrosine kinase is overexpressed and represents a potential therapeutic target in chronic lymphocytic leukemia.Semantic proximity Read ↗

A Genome-Wide CRISPR Screen Identifies Genes Critical for Resistance to FLT3 Inhibitor AC220.Semantic proximity Read ↗

Phosphorylation of SHP2 at Tyr62 Enables Acquired Resistance to SHP2 Allosteric Inhibitors in FLT3-ITD-Driven AML.Semantic proximity Read ↗

Critical individual roles of the BCR and FGFR1 kinase domains in BCR‐FGFR1‐driven stem cell leukemia/lymphoma syndromeSemantic proximity Read ↗

SYK is activated by mutated MYD88 and drives pro-survival signaling in MYD88 driven B-cell lymphomas.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.